Effekten av biologiske mekanismer for aldring på responsvariabilitet til motstandstrening hos eldre voksne (BRIO)
Effekten av biologiske mekanismer for aldring på responsvariabiliteten til motstandstrening hos eldre voksne (BRIO): en randomisert, placebokontrollert studie av progressiv motstandstrening hos eldre voksne.
To critically examine biological, clinical, and behavioral modulators of progressive resistance training-associated exercise response heterogeneity in physical function and whole-body metabolism in older adults.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
A 6-month, single blind, randomized, controlled multi-center clinical trial comparing a Health Education control intervention to a supervised Progressive Resistance Training intervention to test the central hypothesis that biological mechanisms of aging are mediators of exercise response heterogeneity in older adults.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Amanda Tweed
- Telefonnummer: 507-255-6663
- E-post: tweed.amanda@mayo.edu
Studiesteder
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02111
- Rekruttering
- Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University
-
Hovedetterforsker:
- Roger Fielding, PhD
-
Ta kontakt med:
- Arion Mete
- Telefonnummer: 617-556-3237
- E-post: arion.mete@tufts.edu
-
-
Minnesota
-
Rochester, Minnesota, Forente stater, 55905
- Rekruttering
- Mayo Clinic
-
Ta kontakt med:
- Amanda Tweed
- Telefonnummer: 507-255-6663
- E-post: tweed.amanda@mayo.edu
-
Hovedetterforsker:
- Nathan LeBrasseur, Ph.D, MS
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- aged greater than or equal to 65 years
- sedentary (Community Healthy Activities Model Program for Seniors physical activity questionnaire to identify and exclude persons engaged in regular (125 min/week or more) moderate intensity physical activity
- at risk for mobility disability score of less than or equal to 10 (but greater than 3) on the SPPB
- willing to be randomized into HE or PRT
- willing to be transported or transport themselves to the clinical sites for the intervention and assessments
Exclusion Criteria:
- unwillingness to provide informed consent
- participation in lifestyle or pharmacologic intervention trial or structured program of exercise training in the past 6 months
- an SPPB score of less than or equal to 3
- osteoarthritis or condition with joint pain limiting daily life activities
- significant weight loss or gain (7.5% of body weight) in past six months
- current anti-coagulant or anti-platelet therapy (Coumadin, Eliquis, Pradaxa, Xarelto, heparin, Lovenox, Plavix)
- clinically significant abnormality in any of the screening laboratory values, including those identified as outside of the "normal limits', that are deemed to be of concern for participation in the study by the study physician
- acute or terminal illness
- Mini Mental State Exam (MMSE) <23
- myocardial infarction in the previous 6 months or other symptomatic coronary artery disease
- New York Heart Association Class III or IV congestive heart failure
- serious conduction disorder (e.g., 3rd degree heart block), uncontrolled arrhythmia, or new Q waves or ST-segment depressions (>3 mm) on ECG
- chronic obstructive pulmonary disease requiring oxygen therapy
- upper or lower extremity fracture in the previous 6 months
- uncontrolled hypertension (150/90 mm Hg)
- neuromuscular diseases and/or drugs which affect neuromuscular function
- current use of anabolic steroids, growth hormone, replacement androgen therapy, anti-androgen therapy
- allergy to lidocaine
- presence of significant liver or renal disease (eGFR < 45 mL/min)
- diagnosis of type I diabetes mellitus or insulin requiring type 2 diabetes mellitus
- HbA1c > 7%
- BMI <21 or >35 for men or >40 for women
- excessive alcohol intake (>14 alcoholic beverages per wk.)
- current tobacco use
- current participation in any interventional clinical trial
- current use of weight loss medications
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Annen: Progressive Resistance Training
participants will attend exercise session 3 times per week. |
3 times a week |
|
Annen: Health Education
participants will attend health educations classed 1 time per week. |
once a week |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Precisely define the variability in changes in physical function
Tidsramme: baseline, 6 months
|
Measured by the Short Physical Performance Battery (SPPB), a 0-12 categorical scale of walking speed, standing balance, and repeated sit-to-stand time, with higher scores reflecting better physical function. |
baseline, 6 months
|
|
Precisely define the variability in changes in blood glucose concentrations in response to a meal tolerance test
Tidsramme: baseline, 6 months
|
Blood glucose concentrations (millimoles/liter) will be measured in response to a physiologically relevant meal challenge. Lower values are indicative of better metabolic health. |
baseline, 6 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Precisely define the variability in changes in skeletal muscle size.
Tidsramme: baseline, 6 months
|
Measured by computed tomography scans of the mid-thigh. Larger muscle cross-sectional area (cm^2) reflects a greater quantity of skeletal muscle. |
baseline, 6 months
|
|
Precisely define the variability in changes in skeletal muscle strength.
Tidsramme: baseline, 6 months
|
Measured by the one-repetition maximum, in newtons, on a leg press device, with higher scores reflecting greater skeletal muscle strength. |
baseline, 6 months
|
|
Precisely define the variability in changes in six-minute walk distance.
Tidsramme: baseline, 6 months
|
Measured by the distance (meters) walked in six minutes, with longer distances reflecting better physical function. |
baseline, 6 months
|
|
Precisely define the variability in insulin secretion in response to a mixed meal tolerance test.
Tidsramme: baseline, 6 months
|
Blood insulin concentrations (pmol/L) will be measured in response to a physiologically relevant meal challenge. Insulin concentrations in a physiological range reflect better metabolic health, while low insulin concentrations can reflect an impaired insulin response and high insulin concentrations can reflect peripheral insulin resistance. |
baseline, 6 months
|
|
Precisely define the variability in changes in the percentage of glycated hemoglobin in the blood.
Tidsramme: baseline, 6 months
|
Measured by the percentage of glycated hemoglobin in the blood (often referred to as HbA1c). A lower percentage of HbAlc reflects lower blood glucose concentrations over the past two to three months. |
baseline, 6 months
|
|
Precisely define the variability in changes in blood lipids.
Tidsramme: baseline, 6 months
|
Blood lipids, including total cholesterol, low density lipoproteins (LDLs), high density lipoproteins (HDLs), and triglycerides will be measured. Lower levels of total cholesterol (mg/dL), LDLs (mg/dL), and triglycerides (mg/dL), and higher levels of HDLs (mg/dL), are reflective of better metabolic health. |
baseline, 6 months
|
|
Precisely define the variability in changes in waist-to-hip ratio.
Tidsramme: baseline, 6 months
|
The circumference (cm) of the waist and hips will be measured and a ratio will be calculated. A lower waist-to-hip ratio is reflective of a better body composition (less central obesity or visceral fat). |
baseline, 6 months
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Nathan LeBrasseur, Ph.D, MS, Mayo Clinic
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 24-010008
- R01AG089150 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .